RMC No. 119-2022: VAT Exemption for Newly Endorsed COVID-19 Medicines

RMC No. 119-2022 adds Nirmatrelvir + Ritonavir 150 mg + 100 mg tablets for COVID-19 to the VAT-exempt list, effective from FDA publication, impacting healthcare providers and distributors. Businesses and healthcare providers must update their VAT-exempt inventory immediately: the Food and Drug Administration has added Nirmatrelvir + Ritonavir 150 mg + 100 mg film-coated tablets […]

RMC No. 113-2022: Updates to VAT-Exempt Medicines under the CREATE Act Affecting COVID-19 Treatments

RMC No. 113-2022 updates the VAT-exempt medicines list under the CREATE Act, correcting and deleting certain COVID-19 treatments, effective July 1, 2022. Businesses must adjust VAT filings accordingly. Businesses dealing with pharmaceutical sales must immediately review their VAT compliance for medicines prescribed for COVID-19. Recent updates endorsed by the Food and Drug Administration now correct […]